Joseph A. Yanchik III
Joseph Yanchik, a venture partner at ATP, has been founding and funding life science companies for more than 20 years. In 2005, Joe founded ATP portfolio company Tokai Pharmaceuticals, focused on biopharmaceutical treatments for prostate cancer, serving as president and CEO from 2005 to 2008 and then as a director through 2017. Concurrently, Joe founded ATP portfolio company Aileron Therapeutics, focused on developing a novel class of stabilized cell-permeating peptides called stapled peptides, for cancer and other diseases. He established a $1.1 billion partnership between Aileron Therapeutics and Roche Pharmaceuticals and led Aileron from inception to public listing, serving as president, CEO, and director from 2006 to 2018. Previously, Joe served as vice president of corporate development at Mendel Biotechnology, an agricultural biotech company, and founded and served as chief financial officer of Poetic Genetics, a gene therapy company. He began his career practicing corporate and securities law at Cahill Gordon & Reindel, where he specialized in public securities offerings, high-yield debt financings, and M&A. He then moved to Venture Law Group in Menlo Park, where he specialized in financing early-stage life science and technology companies.
Joe received a BBA from Loyola College in Maryland and a J.D. from the Villanova University School of Law, where he was managing editor of the Law Review. He is a member of the New York, California, and District of Columbia bars.